CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

(1) Icahn School Of Medicine At Mount Sinai, New York, United States

(2) University Of Leuven, Leuven, Belgium

(3) Ucsd, La Jolla, United States

(4) Atlanta Gastroenterology Associates, Atlanta, United States

(5) Mcmaster University, Hamilton, Canada

(6) Abbvie Inc, North Chicago, United States



This item was part of UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)